SINGAPORE, February 4. /TASS/. Ho Ching, CEO of Temasek Holding, the largest investment fund in Asia, called the Sputnik V coronavirus vaccine clinical trials results "impressive".

"The 90% efficiency in 21 days after administering - this is impressive," Ho Ching wrote in her Facebook. According to the CEO, "the idea to use different carriers during the second dose appears to be very reasonable."

"This explains why AstraZeneca plans to join forces with the Gamaleia Center for joint development of vaccines," the CEO said.

She also noted that the Russian "research institute and its scientists enjoy high authority and good reputation among scientists and vaccine developers across the globe."

On February 2, The Lancet journal published the results of the third phase of the vaccine’s clinical trials, which make it one of the most efficient and safe in the world. The vaccine’s efficiency is estimated at about 91.6%.

On August 11, 2020, Russia became the first country to register its coronavirus vaccine. Currently, the vaccine is registered in Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary and the UAE.